Avastin advertising contracted before FDA decision

12/13/2011 | Medical Marketing & Media

Roche's Genentech unit reduced spending on journal ads for Avastin well before the FDA revoked approval for the drug to treat breast cancer. Genentech stopped promoting Avastin for breast cancer in August 2010 and reduced spending on journal ads for other indications in 2011, a spokeswoman said.

View Full Article in:

Medical Marketing & Media

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT